Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Journal of Clinical Pharmacy and Pharmaceutical Science Indonesian Journal of Pharmacology and Therapy
Fef Rukminingsih
Unknown Affiliation
Immunology & microbiology Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Correlation between mean arterial pressure (MAP) and length of stay (LoS) of heart failure in-patients with sacubitril/valsartan and ramipril at X Hospital Semarang Hadianti Deliana R; N Setiawati, Maria Caecilia; Fef Rukminingsih
Indonesian Journal of Pharmacology and Therapy Vol 7 No 1 (2026)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.26456

Abstract

Heart failure is a health problem with high morbidity and mortality rates globally and nationally, so optimal therapy is needed to improve clinical outcomes and efficiency. Sacubitril/valsartan (angiotensin receptor neprilysin inhibitor/ARNI) and ramipril (ACE inhibitor/ACEi) have become the therapeutic options in heartfailure patients. However, the effectiveness of both therapies on length of stay (LoS) and changes in mean arterial pressure (MAP) in the Indonesian population has not much studied. This study used an observational retrospective design on the medical record data of heart failure inpatients at X Hospital, Semarang,during January to December 2024 period. All in-patients who received sacubitril/valsartan or ramipril therapy (in combination with beta blockers and aldosterone receptor antagonists) were included, and were differentiated based on changes in MAP (up, down and constant). Correlation statistical analysis was performedwith normality test, Kruskal-Wallis, and Anova tests to correlate the LoS and MAP changes between therapy. A total of 131 patients were categorized by therapy and MAP changes. The average LoS on Sacubitril/valsartan and Ramipril therapy was approximately 5–6 d each for the entire MAP change group. Statistical testsshowed no significant difference between the two therapies for LOS, as well as of MAP changes (p > 0.05). MAP changes (up, down, constant) in heart failure in-patients treated with sacubitril/valsartan and ramipril provided variation in LoS, but the differences were not statistically significant between the two therapies.
Correlation between mean arterial pressure (MAP) and length of stay (LoS) of heart failure in-patients with sacubitril/valsartan and ramipril at X Hospital Semarang Hadianti Deliana R; N Setiawati, Maria Caecilia; Fef Rukminingsih
Indonesian Journal of Pharmacology and Therapy Vol 7 No 1 (2026)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.26456

Abstract

Heart failure is a health problem with high morbidity and mortality rates globally and nationally, so optimal therapy is needed to improve clinical outcomes and efficiency. Sacubitril/valsartan (angiotensin receptor neprilysin inhibitor/ARNI) and ramipril (ACE inhibitor/ACEi) have become the therapeutic options in heartfailure patients. However, the effectiveness of both therapies on length of stay (LoS) and changes in mean arterial pressure (MAP) in the Indonesian population has not much studied. This study used an observational retrospective design on the medical record data of heart failure inpatients at X Hospital, Semarang,during January to December 2024 period. All in-patients who received sacubitril/valsartan or ramipril therapy (in combination with beta blockers and aldosterone receptor antagonists) were included, and were differentiated based on changes in MAP (up, down and constant). Correlation statistical analysis was performedwith normality test, Kruskal-Wallis, and Anova tests to correlate the LoS and MAP changes between therapy. A total of 131 patients were categorized by therapy and MAP changes. The average LoS on Sacubitril/valsartan and Ramipril therapy was approximately 5–6 d each for the entire MAP change group. Statistical testsshowed no significant difference between the two therapies for LOS, as well as of MAP changes (p > 0.05). MAP changes (up, down, constant) in heart failure in-patients treated with sacubitril/valsartan and ramipril provided variation in LoS, but the differences were not statistically significant between the two therapies.
EVALUASI BIAYA KEMOTERAPI PASIEN EARLY BREAST CANCER DI RSUD TUGUREJO SEMARANG PERIODE JULI-DESEMBER 2018 Wilis Rakhmadhanti; Fef Rukminingsih
Journal Clinical Pharmacy and Pharmaceutical Science Vol. 1 No. 1 (2022): April: Journal of Clinical Pharmacy and Pharmaceutical Science
Publisher : Prodi D3 Farmasi Politeknik Katolik Mangunwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61740/jcp2s.v1i1.1

Abstract

Early breast cancer (EBC) is defined as with or without in a breast cancer, but it has not metastasized to wider tissue. Chemotherapy expense  has 59% portion of the total cost of cander patients at the hospital. There were 137 EBC patients visit during January-March 2018 conducted at Tugurejo Regional Hospital Semarang. Therefore, research is needed to evaluate the cost of chemotherapy in EBC patient in Tugurejo  Hospital Semarang. This study was an observational descriptive study with a cross sectional study design. Data sources were gained from Medical Record (MR) data and billing / billing data for National Health Insurance (JKN) participant patients with an EBC diagnosis undergoing chemotherapy at Tugurejo Hospital Semarang in the period July-December 2018. The inclusion criteria for this study was JKN patients with EBC diagnosis age 17 -65 years who did chemotherapy at Tugurejo General Hospital Semarang in the period July-December 2018. Data was processed qualitatively and quantitatively. The results of evaluation of  the cost of chemotherapy for EBC patients at Tugurejo Hospital Semarang in the period July-December 2018 were done with the regimen Doxorubicin-Doxetacel-Fluorouracil (AT-F) Rp 3.683.388,00 ± 193.960, Doxetacel-Epirubicin-Fluorouracil (TE-F) Rp 4.342.914 00 ± 37.614, Fluorouracil-Epirubicin-Cyclofosphamid (FEC) Rp 2.929.464,00 ± 193.960, Fluorouracil-Doxorubicin-Cyclofosphamid (FAC) amounting to Rp2.471.671,00 ± 193.960.  
Co-Authors Hadianti Deliana R N Setiawati, Maria Caecilia Wilis Rakhmadhanti